Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib.

Find People
Find Research
Overview
Tutorials
FAQs
Edit My PROFILE
Login to PROFILES

History

A phase I dose-escalat

Central Nervous System

Contact Us
If you have any questions or feedback please contact us.

Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib.

Tsui DCC, Kavanagh BD, Honce JM, Rossi C, Patil T, Camidge DR. Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib. Clin Lung Cancer. 2022 01; 23(1):e5-e8.

View in: PubMed

subject areas

Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Central Nervous System
Female
Humans
Lung Neoplasms
Meningeal Neoplasms
Middle Aged
Proto-Oncogene Proteins c-ret
Pyrazoles
Pyridines
Pyrimidines

authors with profiles

Brian D Kavanagh
Justin M. Honce
David Ross Camidge
Tejas Patil
Candice B Rossi

Contact Us
CCTSI
About CCTSI
CCTSI Affiliated Institutions
National CTSA Consortium